RVTY (revvity.com) Enterprise Value-to-Revenue Ratio

Official company branding of Revvity Inc (RVTY)

Revvity, Inc. (RVTY) faces trade barriers between the US and China, which complicates logistics. The company's mature technologies provide a foundation for personalized medicine. The company's EV/Sales valuation demonstrates the market scale of the business, with 6490.99 representing the current metric. However, fierce competition in the medtech segment and dumping of consumables are pressuring margins.

RVTY Revvity Inc: Company Value to Revenue in the range 11/23/2025 - 11/20/2026

Financial and market metric breakdowns for PerkinElmer (RVTY)

- share price and expert price forecast:
- business market valuation indicators:
Fundamental company valuation:RVTY (revvity.com)
Core merchandise of Revvity Inc

The EV/Sales multiple determines the value of the entire business, including debt minus cash, per unit of revenue, excluding the impact of financial leverage. Investors utilize this metric to identify asset overvaluation and protect capital from unjustified market expectations. When analyzing the business valuation of Revvity, Inc. (RVTY) through EV/Sales, it is critical to consider the company's expenditures on complex temperature-controlled reagent logistics, which directly impact operational efficiency and final capitalization.

Competitor analysis

A (Agilent) - Company Value to Revenue Ratio|DGX (Quest Diagnostics) - Company Value to Revenue|Illumina Inc (ILMN) - EV/Sales Multiple|Company Value to Revenue EXAS|EV/Sales Multiple Bio-Rad Laboratories Inc|Company Value to Revenue NNNN (Anbio Biotechnology)|SHC (Sotera Health Company) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio QuidelOrtho Inc. QDEL|EV/Sales Multiple OPKO Health Inc OPK|CareDx Inc - EV/Sales Multiple|Business Value to Revenue MRVI (Maravai)|FLGT: EV/Sales Multiple|LAB (Standard BioTools Inc.) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Cytek Biosciences Inc|Enterprise Value-to-Revenue Multiple OraSure OSUR|Company Value to Revenue XGN (Exagen Diagnostics)|Total Company Value-to-Revenue Ratio MDxHealth Inc.|Enterprise Value-to-Revenue Ratio Lucid Diagnostics, Inc. LUCD|Prenetics Global Ltd (PRE) - Enterprise Value-to-Revenue Multiple|Insight Molecular Diagnostics Inc - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple trinitybiotech.com|PRPH (ProPhase) - Company Value to Revenue|Company Value to Revenue Ratio AIMD|Company Value to Revenue CODX|Enterprise Value-to-Revenue Multiple heartsciences.com HSCS|Enterprise Value-to-Revenue Ratio Biomerica Inc. (BMRA)|Total Company Value-to-Revenue Ratio Cardio Diagnostics Holdings|EV/Sales Multiple ONCO (Onconetix Corporation)|Virax Biolabs Group (VRAX) - Enterprise Value-to-Revenue Multiple|bluejaydx.com - EV/Sales Multiple|Aspira Women's Health - Enterprise Value-to-Revenue Coefficient|AXDX (Accelerate Diagnostics) - Company Value to Revenue|Company Value to Revenue CENTOGENE, N.V.|Enterprise Value-to-Revenue Ratio enzo.com|EV/Sales Multiple Fresh2 Group Limited|EV/Sales Multiple GENE|23andMe Holding Co. - Company Value to Revenue Ratio|Psychemedics Inc - Company Value to Revenue